Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Desonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 8/20 | 0.70 |
| ▸ | PGR | P06401 | 6/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.67 |
| ▸ | LMNA | P02545 | 5/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.64 |
| ▸ | AR | P10275 | 2/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.54 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.54 |
| ▸ | IL5 | P05113 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desonide SCHEMBL28118984 | 1.00 | NR3C1 (0.70) | NR3C1PGRCYP3A4LMNAHIF1A | |
| Desonide SCHEMBL11778722 | 0.87 | CYP3A4 (0.73) | NR3C1PGRCYP3A4LMNAHIF1A | |
| Desonide SCHEMBL2115498 | 0.86 | CYP3A4 (0.75) | NR3C1PGRCYP3A4LMNAHIF1A | |
| Fluocinolone Acetonide SCHEMBL22807167 | 0.85 | NR3C1 (0.73) | NR3C1PGRCYP3A4LMNAHIF1A | |
| Desonide SCHEMBL28086567 | 0.85 | NR3C1 (0.71) | NR3C1PGRCYP3A4LMNAHIF1A | |
| Triamcinolone Acetonide SCHEMBL7988975 | 0.84 | NR3C1 (0.70) | NR3C1PGRCYP3A4LMNAHIF1A | |
| Triamcinolone Acetonide SCHEMBL9987506 | 0.84 | CYP3A4 (0.75) | NR3C1PGRCYP3A4LMNAHIF1A | |
| Triamcinolone Acetonide SCHEMBL20915153 | 0.84 | HIF1A (0.77) | NR3C1PGRCYP3A4LMNAHIF1A | |
| Desonide SCHEMBL12235707 | 0.84 | NR3C1 (1.00) | NR3C1PGRCYP3A4LMNAHIF1A | |
| Desonide SCHEMBL21570018 | 0.84 | NR3C1 (1.00) | NR3C1PGRCYP3A4LMNAHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165020-A1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-05-23 | — | — | US | claimed |
| EP-4360653-A2 | LIQUISOFT CAPSULES | Patheon Softgels Inc. (US) | 2024-05-01 | — | — | EP | claimed |
| US-11872307-B2 | Liquisoft capsules | PATHEON SOFTGELS INC. (US) | 2024-01-16 | — | — | US | claimed |
| EP-3682872-B1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-01-03 | — | — | EP | claimed |
| WO-2023205619-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-26 | — | — | WO | claimed |
| US-20220211616-A1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2022-07-07 | — | — | US | claimed |
| EP-3970726-A1 | METHODS OF TREATMENT FOR ESOPHAGEAL INFLAMMATION | ViroPharma Biologics LLC (US) | 2022-03-23 | — | — | EP | claimed |
| EP-3884963-A1 | NAPROXEN/DEXAMETHASONE-BASED NANOPARTICLES | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2021-09-29 | — | — | EP | claimed |
| EP-3682872-A1 | LIQUISOFT CAPSULES | Patheon Softgels Inc. (US) | 2020-07-22 | — | — | EP | claimed |
| EP-2328553-B1 | CORTICOSTEROIDS FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT | UNIV CALIFORNIA (US) | 2020-06-10 | — | — | EP | claimed |
| WO-2016205172-A1 | SOFT LOZENGES COMPRISING CORTICOSTEROIDS | BANNER LIFE SCIENCES LLC (US) | 2016-12-22 | — | — | WO | claimed |
| US-20160361320-A1 | SOFT LOZENGES COMPRISING CORTICOSTEROIDS | PATHEON SOFTGELS INC. | 2016-12-15 | — | — | US | claimed |
| US-20160279056-A1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC | 2016-09-29 | — | — | US | claimed |
| WO-2016154503-A1 | LIQUISOFT CAPSULES | BANNER LIFE SCIENCES LLC (US) | 2016-09-29 | — | — | WO | claimed |
| EP-2585075-A2 | METHODS OF TREATMENT FOR ESOPHAGEAL INFLAMMATION | Meritage Pharma, Inc. (US) | 2013-05-01 | — | — | EP | claimed |
| US-20120164080-A1 | METHODS OF TREATMENT FOR ESOPHAGEAL INFLAMMATION | MERITAGE PHARMA, INC. (US) | 2012-06-28 | — | — | US | claimed |
| EP-2440210-A2 | METHODS FOR TREATING GASTROINTESTINAL DISORDERS | Meritage Pharma, Inc. (US) | 2012-04-18 | — | — | EP | claimed |
| WO-2011163614-A2 | METHODS OF TREATMENT FOR ESOPHAGEAL INFLAMMATION | MERITAGE PHARMA, INC. (US) | 2011-12-29 | — | — | WO | claimed |
| US-20110097401-A1 | METHODS FOR TREATING GASTROINTESTINAL DISORDERS | MERITAGE PHARMA, INC. (US) | 2011-04-28 | — | — | US | claimed |
| WO-2010144865-A2 | METHODS FOR TREATING GASTROINTESTINAL DISORDERS | MERITAGE PHARMA, INC. (US) | 2010-12-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160279056-A1 | LIQUISOFT CAPSULES | LCT, SI, PGA5 | NR3C1 1020/4885PGR 1253/4885CYP3A4 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.